BLA 761445 · Sanofi-Aventis U.S. LLC
Sarclisa Escena
Isatuximab-Irfc · Single-Dose · CD38-directed Cytolytic Antibody
OrphanLast checked: Nov 20, 2026Latest source record: Jul 9, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Jul 9, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
107
21 Phase 3, 30 recruiting
FAERS reports
54
47 serious, 6 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 10, 2026.
SARCLISA ESCENA is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including lenalidomide and a proteasome inhibitor. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy. in combination with bortezomib, lenalidomide, and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT). SARCLISA ESCENA is a CD38-directed cytolytic antibody indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including lenalidomide and a proteasome inhibitor. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy. in combination with bortezomib, lenalidomide and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT). ( 1 )
Mechanism: Isatuximab-irfc is an IgG1-derived monoclonal antibody that binds to CD38 expressed on the surface of hematopoietic and tumor cells, including multiple myeloma cells. Isatuximab-irfc induces apoptosis of tumor cells and activation of immune effector mechanisms including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement dependent cytotoxicity (CDC). Isatuximab-irfc inhibits the ADP-ribosyl cyclase activity of CD38. Isatuximab-irfc can activate natural killer (NK) cells in the absence of CD38-positive target tumor cells and...
Therapeutic areas: Hematology and blood cancers
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- SARCLISA ESCENA · ISATUXIMAB-IRFC 1400MG/10ML (140MG/ML) · VIAL, SINGLE-DOSE · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Isatuximab" as an intervention, any sponsor and status, largest first.
- A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic LeukemiaPivotal-lookingRecruiting
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT06860269 · 1,200 participants (planned) · Start May 6, 2025 · Primary completion Mar 15, 2035
Drug: Randomization + Blinatumomab + chemotherapy; Randomization + Isatuximab + Standard frontline T-ALL chemotherapy backbone and 1 more · For: Acute Lymphoblastic Leukemia
Sites: Paris, France
- MInimal Residual Disease Adapted StrategyPivotal-lookingActive, not recruiting
Intergroupe Francophone du MyelomeResearch network
NCT04934475 · 791 participants · Start Dec 8, 2021 · Primary completion Sep 30, 2024
Drug: Isatuximab · For: Multiple Myeloma
Sites: Brussels, Belgium; Charleroi, Belgium; Haine-Saint-Paul, Belgium · 73 sites in all
- To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple MyelomaPivotal-lookingNot yet recruiting
Kite, A Gilead CompanyGilead Sciences (GILD)
NCT07903506 · 750 participants (planned) · Start Feb 2027 · Primary completion Mar 2039
Drug: Anitocabtagene Autoleucel; Isatuximab and 6 more · For: Newly Diagnosed Multiple Myeloma
- Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCTPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07764978 · 750 participants (planned) · Start Jun 26, 2026 · Primary completion Jan 11, 2029
Drug: AZD0120; Daratumumab and 6 more · For: Newly Diagnosed Multiple Myeloma
Sites: Gilbert, Arizona; Phoenix, Arizona; Tucson, Arizona · 124 sites in all
- D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMMPivotal-lookingRecruiting
Dana-Farber Cancer InstituteAcademic, hospital or other
NCT07624513 · 720 participants (planned) · Start Aug 31, 2026 · Primary completion Oct 1, 2033
Drug: Isatuximab; Iberdomide and 4 more · For: Multiple Myeloma
Sites: Boston, Massachusetts · 3 sites in all
- Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)Pivotal-lookingActive, not recruiting
University of Heidelberg Medical CenterAcademic, hospital or other
NCT03617731 · 662 participants · Start Oct 18, 2018 · Primary completion Jun 2028
Drug: Lenalidomide; Bortezomib and 2 more · For: Multiple Myeloma
Sites: Aachen, Germany; Bad Saarow, Germany; Berlin, Germany · 72 sites in all
- Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple MyelomaPivotal-lookingRecruiting
Canadian Cancer Trials GroupResearch network
NCT06182774 · 570 participants (planned) · Start Apr 10, 2024 · Primary completion Jan 31, 2032
Drug: Daratumumab; Lenalidomide and 2 more · For: Multiple Myeloma
Sites: Edmonton, Canada; Kelowna, Canada; Vancouver, Canada · 31 sites in all
- SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMMPivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT05405166 · 531 participants · Start Jun 23, 2022 · Primary completion Nov 6, 2024
Drug: Isatuximab IV; Isatuximab SC and 7 more · For: Plasma Cell Myeloma Recurrent
Sites: Aurora, Colorado; Jacksonville, Florida; Plantation, Florida · 128 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- neutropenia9
- urinary tract infection6
- neutrophil count decreased5
- upper respiratory tract infection4
- abdominal pain3
- drug hypersensitivity3
- headache3
- infusion related reaction3
- malaise3
- off label use3
- platelet count decreased3
- pneumonia3
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2021 | 2 |
| 2022 | 4 |
| 2023 | 11 |
| 2024 | 17 |
| 2025 | 11 |
| 2026 | 9 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Facon T, Dimopoulos MA, Leleu XP, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial.
Leleu X, Hulin C, Lambert J, et al. · Nat Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial.
Mai EK, Bertsch U, Pozek E, et al. · J Clin Oncol 2025 · Randomized Controlled Trial, Multicenter Study
- Isatuximab Monotherapy for Desensitization in Highly Sensitized Patients Awaiting Kidney Transplant.
Vincenti F, Bestard O, Brar A, et al. · J Am Soc Nephrol 2024 · Clinical Trial, Phase II, Clinical Trial, Phase I
- Measurable Residual Disease-Guided Therapy in Newly Diagnosed Myeloma.
Perrot A, Lambert J, Hulin C, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study.
Ailawadhi S, pička I, Spencer A, et al. · J Clin Oncol 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: Sanofi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.